A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Hepatitis C, Chronic

In brief

The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.

Key facts

Study ID
NCT00088140
Run by
Conatus Pharmaceuticals Inc.
People needed
204
Starts
2004-07-01
Expected to finish
2005-10-01
Last updated by the study team
2012-08-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.